Remarks

This paper amends claims 1 and 8, cancels claim 4 and adds new claims 11-19 so that claims 1-3 and 5-19 are pending in the case. No new matter is believed to be added by this amendment.

It is requested that the amendments to the claims be entered and that the case be examined on the merits. Should any questions arise, the P.T.O. is requested to contact the undersigned attorney.

Respectfully submitted,



Donald R. Holland
Reg. No. 35,197
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500

AMENDED CLAIMS IN MARKED UP VERSION:

1. (Amended) A method for [enhancing] enhanced magnetic resonance imaging of a target tissue [the acoustic reflectivity of a surface] *in vivo* in a patient, the method comprising:

(1) administering systemically to the patient [said surface]:

(a) a site-specific ligand; and

(b) a liquid emulsion having an outer surfactant coating [composed of a material selected from the group consisting of a natural or synthetic phospholipid, a fatty acid, cholesterol, lipolipid, sphingomyelin, tocopherol, glucolipid, stearylamine, cardiolipin, a lipid with ether or ether linked fatty acids and a polymerized lipid;

said ligand being conjugated to said liquid emulsion] ; said ligand being conjugated to said liquid emulsion; wherein upon binding to the target tissue, the ligand-liquid emulsion conjugate enhances magnetic resonance imaging of the target tissue; and [whereby the resulting liquid emulsion conjugate is bound to said surface thereby causing enhancement of the acoustic reflectivity thereof for ultrasonic imaging or ultrasonic diagnostic applications]

(2) detecting an enhanced magnetic resonance image of the ligand-liquid emulsion conjugate bound to the target tissue.

8. (Amended) A composition for enhancing magnetic resonance imaging of a target tissue *in vivo* in a patient [formed *in vivo* and enhancing the acoustic reflectivity of a surface to which it is bound], said composition comprising:

(a) a site-specific ligand; and

(b) a liquid fluorocarbon emulsion having an outer surfactant coating [composed of a material selected from the group consisting of a natural or synthetic phospholipid, a fatty acid, cholesterol, lipolipid, sphingomyelin, tocopherol, glucolipid, stearylamine, cardiolipin, a lipid with ether or ether linked fatty acids and a polymerized lipid]; said ligand being conjugated to said liquid emulsion wherein the composition is suitable for systemic administration to a patient; and wherein upon imaging the target

tissue by magnetic resonance, an enhanced image of [with] the [resulting] ligand-liquid emulsion conjugate bound to the target tissue can be detected [being bound to said surface thereby causing enhancement of the acoustic reflectivity thereof for ultrasonic imaging or ultrasonic diagnostic applications].